MCID: SPN052
MIFTS: 60

Spondyloarthropathy

Categories: Bone diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Spondyloarthropathy

MalaCards integrated aliases for Spondyloarthropathy:

Name: Spondyloarthropathy 12 15 40
Spondylarthropathies 44 73
Spondyloarthropathy, Susceptibility to 29
Spondarthropathy 12
Spondylarthrosis 12
Spondylarthritis 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1123
MeSH 44 D025242

Summaries for Spondyloarthropathy

MalaCards based summary : Spondyloarthropathy, also known as spondylarthropathies, is related to spondyloarthropathy 1 and anterior uveitis, and has symptoms including sciatica An important gene associated with Spondyloarthropathy is SPDA2 (Spondyloarthropathy, Susceptibility To, 2), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Infliximab and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Spondyloarthropathy or spondyloarthrosis refers to any joint disease of the vertebral column. As such,... more...

Related Diseases for Spondyloarthropathy

Diseases in the Spondyloarthropathy family:

Spondyloarthropathy 1 Spondyloarthropathy 2
Spondyloarthropathy 3 Juvenile Spondyloarthropathy

Diseases related to Spondyloarthropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 338)
# Related Disease Score Top Affiliating Genes
1 spondyloarthropathy 1 33.4 HLA-B IL17A MMP3 MRAP TNF
2 anterior uveitis 31.0 HLA-A HLA-B IL6
3 peritonitis 30.5 IL10 IL6 TNF
4 spondylitis 30.5 HLA-B HLA-C IL17A IL6 TNF
5 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.4 IFNG IL10 IL17A
6 reactive arthritis 30.4 HLA-B IFNG IL10 IL6 TNF
7 chlamydia 30.2 IFNG IL10 IL6 TNF
8 lyme disease 30.2 IL17A IL6 TNF
9 ulcerative colitis 30.2 IL10 IL2 IL6 TNF
10 mixed connective tissue disease 30.1 IFNG IL10 IL6 TNF
11 myocarditis 30.1 HLA-B IL6 TNF
12 connective tissue disease 30.0 IFNG IL10 IL6 TNF
13 uveitis 30.0 HLA-B IFNG IL10 IL17A IL4 TNF
14 herpes zoster 30.0 HLA-A IFNG IL10 IL2
15 conjunctivitis 29.8 IFNG IL2 IL4 IL6
16 arthritis 29.6 IFNG IL10 IL17A IL6 MMP3 TNF
17 brucellosis 29.5 IFNG IL10 IL2 IL4 IL6 TNF
18 synovitis 29.4 IL6 MMP3 TNF TNFSF11
19 myeloma, multiple 29.3 IL2 IL6 TNF TNFSF11
20 psoriatic arthritis 28.9 HLA-B HLA-C IL17A IL6 MMP3 TNF
21 colitis 28.9 IFNG IL10 IL17A IL2 IL4 IL6
22 osteoporosis 28.7 IFNG IL6 MMP3 TNF TNFSF11
23 systemic lupus erythematosus 28.5 IFNG IL10 IL17A IL2 IL4 IL6
24 psoriasis 28.4 HLA-C IFNG IL10 IL17A IL2 IL4
25 multiple sclerosis 28.3 IFNG IL10 IL17A IL2 IL4 IL6
26 inflammatory bowel disease 28.2 HLA-B IFNG IL10 IL17A IL2 IL4
27 autoimmune disease 28.0 HLA-B IFNG IL10 IL17A IL2 IL4
28 rheumatoid arthritis 27.9 HLA-B IFNG IL10 IL17A IL2 IL4
29 juvenile spondyloarthropathy 12.3
30 spondyloarthropathy 2 12.0
31 spondyloarthropathy 3 12.0
32 spondylarthropathy 11.1
33 phenytoin or carbamazepine toxicity 11.0 HLA-A HLA-B
34 punctate inner choroidopathy 11.0 IL10 TNF
35 postherpetic neuralgia 10.9 HLA-A HLA-B
36 oral tuberculosis 10.9 IL2 TNF
37 ossification of the posterior longitudinal ligament of spine 10.9
38 czech dysplasia 10.9
39 atrial tachyarrhythmia with short pr interval 10.9 HLA-A HLA-B
40 microscopic polyangiitis 10.8 HLA-B IL10 TNF
41 multifocal choroiditis 10.8 IL10 TNF
42 scorpion envenomation 10.8 IL6 TNF
43 staphylococcal toxic shock syndrome 10.8 IFNG TNF
44 nontuberculous mycobacterial lung disease 10.8 HLA-A HLA-B TNF
45 mycoplasmal pneumonia 10.8 IFNG IL4
46 cytomegalovirus retinitis 10.8 HLA-B IFNG TNF
47 variola major 10.7 IFNG IL2
48 trichosporonosis 10.7 IFNG IL17A TNF
49 leukomalacia 10.7 IL6 TNF
50 transient hypogammaglobulinemia 10.7 IL10 TNF

Graphical network of the top 20 diseases related to Spondyloarthropathy:



Diseases related to Spondyloarthropathy

Symptoms & Phenotypes for Spondyloarthropathy

UMLS symptoms related to Spondyloarthropathy:


sciatica

GenomeRNAi Phenotypes related to Spondyloarthropathy according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.14 HLA-C HLA-A HLA-B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.14 HLA-A HLA-C HLA-B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.14 HLA-A HLA-C HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.14 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.14 HLA-C
6 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.14 HLA-C HLA-A HLA-B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.14 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.14 HLA-C HLA-A HLA-B
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.14 HLA-C HLA-A HLA-B
10 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.14 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.14 HLA-C HLA-A HLA-B
12 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.14 HLA-C
13 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.14 HLA-C HLA-A HLA-B
14 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.14 HLA-C HLA-A HLA-B
15 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.14 HLA-C

MGI Mouse Phenotypes related to Spondyloarthropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.8 IL17A IL2 IL4 IL6 TNF IFNG
2 neoplasm MP:0002006 9.63 IL2 IL6 TNF TNFSF11 IFNG IL10
3 no phenotypic analysis MP:0003012 9.5 IL17A IL2 IL4 TNF TNFSF11 IFNG
4 respiratory system MP:0005388 9.23 IL17A IL2 IL4 IL6 TNF TNFSF11

Drugs & Therapeutics for Spondyloarthropathy

Drugs for Spondyloarthropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 276)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 170277-31-3
2
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 169590-42-5 2662
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
4
Sulfasalazine Approved Phase 4,Phase 2,Phase 3,Phase 1 599-79-1 5353980 5359476
5
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 185243-69-0
6
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
7
Adalimumab Approved Phase 4,Phase 2,Phase 3,Not Applicable 331731-18-1 16219006
8
Pamidronate Approved Phase 4 40391-99-9 4674
9
Hydroxychloroquine Approved Phase 4,Phase 3 118-42-3 3652
10
Menthol Approved Phase 4,Phase 3,Not Applicable 2216-51-5 16666
11
Tramadol Approved, Investigational Phase 4,Not Applicable 27203-92-5 33741
12
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Not Applicable 15307-86-5 3033
13
Acetaminophen Approved Phase 4,Not Applicable,Early Phase 1 103-90-2 1983
14
Aceclofenac Approved, Investigational Phase 4 89796-99-6
15
Apremilast Approved, Investigational Phase 4,Phase 3,Phase 2 608141-41-9 11561674
16
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
18 beta-endorphin Phase 4
19 Analgesics Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
20 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Adrenocorticotropic Hormone Phase 4
22 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
23 Natriuretic Agents Phase 4
24 Natriuretic Peptide, Brain Phase 4
25 Cyclooxygenase 2 Inhibitors Phase 4,Phase 3,Not Applicable
26 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
27 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
28 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Vaccines Phase 4,Phase 2
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
35 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
36 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Not Applicable
43 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
44 Melanocyte-Stimulating Hormones Phase 4
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Not Applicable
46 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Mitogens Phase 4

Interventional clinical trials:

(show top 50) (show all 612)
# Name Status NCT ID Phase Drugs
1 Danish Multicenter Study of Adalimumab in Spondyloarthritis Unknown status NCT00477893 Phase 4 Adalimumab;Placebo
2 Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Unknown status NCT02364479 Phase 4 etanercept;etanercept (half dose);placebo
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
5 Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
6 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
7 Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
8 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
9 Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
10 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
11 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Completed NCT03190603 Phase 4 Celecoxib
12 Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
13 A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis Completed NCT01298531 Phase 4 etanercept;etanercept;placebo
14 A Study of the Use of the Madrid Ultrasound Scoring System in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis Completed NCT02960035 Phase 4 etanercept;etanercept (half dose);placebo
15 A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment Completed NCT02897115 Phase 4
16 Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis Completed NCT01029847 Phase 4 Adalimumab;Placebo
17 Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy Completed NCT00420303 Phase 4 Etanercept
18 TNFalfa Blocking Treatment of Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
19 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
20 The NOR-SWITCH Study Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
21 Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
22 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study Completed NCT02915354 Phase 4 Etanercept
23 Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis Completed NCT00715091 Phase 4 diclophenac;diclophenac
24 HUmira in Psoriatic Arthritis Completed NCT01465438 Phase 4 Adalimumab
25 Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis Completed NCT00245960 Phase 4 etanercept
26 A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
27 Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis Completed NCT00432406 Phase 4 Infliximab;Etanercept
28 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
29 The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Completed NCT01668004 Phase 4
30 REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®) Completed NCT00127842 Phase 4 Etanercept
31 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
32 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice Completed NCT01147874 Phase 4
33 Effect of Anti-TNF (Alpha) Treatment on Vascular Stiffness in Ankylosing Spondylitis (AS) Completed NCT01212653 Phase 4 Simponi
34 Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis Completed NCT00953979 Phase 4 kunxian capsule
35 Efficacy and Safety Study of Infliximab (Remicade) to Treat Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
36 Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
37 Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED) Completed NCT00779935 Phase 4
38 A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED) Completed NCT00779012 Phase 4
39 Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED) Completed NCT00778869 Phase 4
40 Tramadol/Acetaminophen(Ultracet) AS add-on Therapy in the Treatment of Patients With Ankylosing Spondylitis Completed NCT00647517 Phase 4 Ultracet
41 Infliximab and Methotrexate in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
42 Study Evaluating Etanercept in Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
43 An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
44 Combination Methotrexate and Infliximab Completed NCT00432432 Phase 4 Infliximab and MTX
45 Centocor Microarray Study of Patients Completed NCT00462072 Phase 4 Infliximab
46 Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
47 Extension Study Evaluating Etanercept in Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
48 Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis Completed NCT00161655 Phase 4 Etanercept;Methotrexate
49 Enbrel® in Psoriatic Arthritis Completed NCT00111124 Phase 4 Enbrel®
50 Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)

Search NIH Clinical Center for Spondyloarthropathy

Cochrane evidence based reviews: spondylarthropathies

Genetic Tests for Spondyloarthropathy

Genetic tests related to Spondyloarthropathy:

# Genetic test Affiliating Genes
1 Spondyloarthropathy, Susceptibility to 29

Anatomical Context for Spondyloarthropathy

MalaCards organs/tissues related to Spondyloarthropathy:

41
Bone, Testes, T Cells, Endothelial, Heart, Skin, Colon

Publications for Spondyloarthropathy

Articles related to Spondyloarthropathy:

(show top 50) (show all 589)
# Title Authors Year
1
Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn's disease-associated spondyloarthropathy. ( 29705819 )
2018
2
Management of Uveitis in Spondyloarthropathy: Current Trends. ( 29272246 )
2018
3
Pictorial Representation of Joint Involvement in Different Types of Spondyloarthropathy. ( 29342025 )
2018
4
Stability of fatigue, pain, patient global assessment and the Bath Ankylosing Spondylitis Functional Index (BASFI) in spondyloarthropathy patients with stable disease according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). ( 29299630 )
2018
5
Similar subclinical enthesitis in celiac and inflammatory bowel diseases by ultrasound suggests a gut enthesis axis independent of spondyloarthropathy spectrum. ( 29741671 )
2018
6
Quantifying the genetic risk for the development of axial spondyloarthropathy: could this become a diagnostic tool? ( 29702496 )
2018
7
Detection of Crohn Disease in Patients with Spondyloarthropathy: The SpACE Capsule Study. ( 29449505 )
2018
8
Comparison of patients with familial Mediterranean fever accompanied with sacroiliitis and patients with juvenile spondyloarthropathy. ( 28980897 )
2017
9
Back to Basics: Clinical versus Radiologic Recognition of Spondyloarthropathy. ( 28572477 )
2017
10
Cervical epidural injection in management of refractory pain and stiffness in spondyloarthropathy: A case report series. ( 28742241 )
2017
11
ACR Appropriateness Criteria(Ar) Chronic BackA PainA Suspected Sacroiliitis-Spondyloarthropathy. ( 28473095 )
2017
12
Seronegative Spondyloarthropathy ( 29083692 )
2017
13
An Unusual Cause of Myelopathy: Ochronotic Spondyloarthropathy with Positive HLA B27. ( 28240677 )
2017
14
Quadriplegia caused by an epidural abscess occurring at the same level of cervical destructive spondyloarthropathy: a case report. ( 28068970 )
2017
15
The Fascinating Paradox of Osteoporosis in Axial Spondyloarthropathy. ( 28966207 )
2017
16
Radiographic changes of cervical destructive spondyloarthropathy in long-term hemodialysis patients: A 9-year longitudinal observational study. ( 28373631 )
2017
17
Switching from Other Biologics to ZRC3197 (Adalimumab Biosimilar) in Patients with Spondyloarthropathy: A Prospective Evaluation from Real-Life Clinical Practice. ( 28836748 )
2017
18
Surgical Management for Destructive Atlantoaxial Spondyloarthropathy in Long-Term Hemodialysis Patients. ( 27771479 )
2017
19
Spondyloarthropathy: diagnostic imaging criteria for the detection of sacroiliitis. ( 28894334 )
2017
20
MRI assessment of sacroiliitis for the diagnosis of axial spondyloarthropathy: comparison of fat-saturated T2, STIR and contrast-enhanced sequences. ( 28749173 )
2017
21
Role of technetium-99m methylene diphosphonate SPECT/CT in the detection of sacroiliitis in patients with spondyloarthropathy - comparison with clinical markers and MRI. ( 28798229 )
2017
22
Co-treatment with golimumab and vedolizumab to treat severe UC and associated spondyloarthropathy. ( 29088342 )
2017
23
Dialysis-Related Spondyloarthropathy with Cervical Amyloidoma. ( 27491462 )
2016
24
Spondyloarthropathy-Like Findings and Diffuse Osteosclerosis as the Presenting Feature of Pseudohypoparathyroidism. ( 26906309 )
2016
25
Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option? ( 27215204 )
2016
26
The prevalence of spondyloarthropathy in fibromyalgia patients. ( 27919196 )
2016
27
Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis. ( 27490376 )
2016
28
Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthropathy, Following Lyme Disease. ( 27636905 )
2016
29
Recombinant Salmonella typhimurium Outer membrane protein A is recognized by synovial fluid CD8 cells and stimulates synovial fluid mononuclear cells to produce IL17/IL23 in patients with Reactive arthritis and undifferentiated spondyloarthropathy. ( 27060348 )
2016
30
Improving recognition of spondyloarthropathy in primary care: an unmet need. ( 26823529 )
2016
31
High Prevalence of Back Pain and Axial Spondyloarthropathy in Patients with Hidradenitis Suppurativa. ( 27649417 )
2016
32
Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. ( 27588089 )
2016
33
Challenges of cervical reconstruction for destructive spondyloarthropathy in renal osteodystrophy. ( 27052255 )
2016
34
Ultrasound-guided retro-calcaneal bursa corticosteroid injection for refractory Achilles tendinitis in patients with seronegative spondyloarthropathy: efficacy and follow-up study. ( 26894910 )
2016
35
Evaluation of treatments for sacroiliitis in spondyloarthropathy using the Spondyloarthritis Research Consortium Canada scoring system. ( 26832154 )
2016
36
Prognosis and adjacent segment disease after lumbar spinal fusion surgery for destructive spondyloarthropathy in long-term hemodialysis patients. ( 28027828 )
2016
37
Case 234: Neuropathic Spondyloarthropathy. ( 27643771 )
2016
38
Prevalence of axial spondyloarthropathy among patients suffering from Fibromyalgia - an MRI study with application of the ASAS classification criteria. ( 27390225 )
2016
39
Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) data. ( 26948670 )
2016
40
Comparison on radiographic progression for 5 years between juvenile onset ankylosing spondylitis and adult onset ankylosing spondylitis: an observational study of the Korean SpondyloArthropathy Registry (OSKAR) data. ( 27051061 )
2016
41
Development of spondyloarthropathy following episodes of macrophage activation syndrome in children with heterozygous mutations in haemophagocytic lymphohistiocytosis-associated genes. ( 27383696 )
2016
42
Trafficking of antigens from gut to sacroiliac joints and spine in reactive arthritis and spondyloarthropathies: Mainly through lymphatics? ( 26968111 )
2016
43
Different Contributions of CDKAL1, KIF21B, and LRRK2/MUC19 Polymorphisms to SAPHO Syndrome, Rheumatoid Arthritis, Ankylosing Spondylitis, and Seronegative Spondyloarthropathy. ( 27936930 )
2016
44
Kinases inhibitors and small molecules: A new treatment tool for axial spondyloarthropathy? ( 27149917 )
2016
45
Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors. ( 26337851 )
2015
46
Diagnostics of Sacroiliitis According to ASAS Criteria: A Comparative Evaluation of Conventional Radiographs and MRI in Patients with a Clinical Suspicion of Spondyloarthropathy. Preliminary Results. ( 26082819 )
2015
47
Surgical Treatment for Atlanto-Occipital Subluxation due to Destructive Spondyloarthropathy in a Patient Undergoing Long-Term Hemodialysis. ( 26240725 )
2015
48
Juvenile spondyloarthropathy: an important clinical lesson to remember. ( 26677159 )
2015
49
P628. Anti-TNF treatment and renal cell carcinoma in patients with inflammatory bowel disease, rheumatoid arthritis and spondyloarthropathy: trigger or cure? ( 25718130 )
2015
50
MRI of inflammatory spondyloarthropathy following traumatic cauda equina syndrome. ( 25900290 )
2015

Variations for Spondyloarthropathy

Expression for Spondyloarthropathy

Search GEO for disease gene expression data for Spondyloarthropathy.

Pathways for Spondyloarthropathy

Pathways related to Spondyloarthropathy according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 ALDOA HLA-A HLA-B HLA-C IFNG IL10
2
Show member pathways
13.5 IFNG IL10 IL17A IL2 IL4 IL6
3
Show member pathways
13.41 IL10 IL17A IL2 IL4 IL6 TNF
4
Show member pathways
13.32 IL10 IL17A IL2 IL4 IL6 TNF
5
Show member pathways
13.14 HLA-A HLA-B HLA-C IFNG IL10 IL17A
6
Show member pathways
13.03 HLA-A HLA-B HLA-C IL2 IL4 IL6
7
Show member pathways
12.8 HLA-A HLA-B HLA-C IFNG IL2 IL4
8
Show member pathways
12.65 IFNG IL10 IL17A IL2 IL6 TNF
9 12.61 IFNG IL10 IL17A IL2 IL4 TNF
10
Show member pathways
12.6 HLA-A HLA-B HLA-C IL6 TNF
11
Show member pathways
12.6 HLA-A HLA-B HLA-C IFNG IL10 IL17A
12
Show member pathways
12.56 HLA-A HLA-B HLA-C IFNG IL2 IL4
13
Show member pathways
12.52 HLA-A HLA-B HLA-C IFNG
14 12.48 HLA-A HLA-B HLA-C IL2 IL6 TNF
15
Show member pathways
12.46 IFNG IL10 IL17A IL2 IL4 IL6
16
Show member pathways
12.43 IFNG IL10 IL17A IL2 IL4 IL6
17
Show member pathways
12.4 IFNG IL2 IL4 IL6 TNF
18
Show member pathways
12.39 IFNG IL17A IL4 IL6 MMP3 TNF
19 12.36 HLA-A HLA-B HLA-C IFNG IL10
20
Show member pathways
12.32 IFNG IL10 IL17A IL2 IL6 TNF
21
Show member pathways
12.28 IFNG IL10 IL4 TNF
22 12.26 IFNG IL10 IL6 TNF
23
Show member pathways
12.24 IL10 IL2 IL6 TNF
24
Show member pathways
12.22 IFNG IL4 IL6 TNF
25 12.21 ALDOA IL10 IL6 TNF
26 12.2 HLA-A HLA-B HLA-C IL6
27
Show member pathways
12.14 IFNG IL10 IL17A IL2 IL4 IL6
28 12.08 IFNG IL2 IL4 IL6 TNF
29
Show member pathways
12.03 HLA-A IFNG IL2 IL4
30 12 IFNG IL10 IL2 IL4 IL6 TNF
31 11.97 IL10 IL17A IL4 IL6 MMP3 TNF
32 11.96 IFNG IL10 IL6 TNF
33 11.94 IFNG IL10 IL2 IL6
34 11.93 IL6 MMP3 TNF
35
Show member pathways
11.92 HLA-A HLA-B HLA-C IFNG IL10 IL17A
36 11.9 ALDOA IFNG IL6
37 11.88 IL4 IL6 TNF
38 11.88 IFNG IL2 IL4 IL6
39
Show member pathways
11.84 IFNG IL2 IL4 TNF
40 11.84 IFNG IL17A IL6 MMP3 TNF TNFSF11
41 11.82 IFNG IL10 IL2 IL6 TNF
42 11.77 IL10 IL6 TNF
43
Show member pathways
11.73 HLA-A IFNG IL2 TNF
44
Show member pathways
11.72 IFNG IL2 IL6 MMP3 TNF
45 11.7 IFNG IL10 IL17A IL2 IL4 TNF
46 11.69 IL4 IL6 TNF
47 11.64 IFNG IL2 IL6 TNF
48 11.62 IL10 IL4 IL6 TNF
49 11.61 IFNG IL10 IL6 TNF
50 11.58 IFNG IL10 IL2 IL4

GO Terms for Spondyloarthropathy

Cellular components related to Spondyloarthropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 ALDOA IFNG IL10 IL17A IL2 IL4
2 recycling endosome membrane GO:0055038 9.58 HLA-A HLA-B HLA-C
3 phagocytic vesicle membrane GO:0030670 9.54 HLA-A HLA-B HLA-C
4 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-A HLA-B HLA-C
5 extracellular space GO:0005615 9.36 ALDOA IFNG IL10 IL17A IL2 IL4
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-A HLA-B HLA-C
7 MHC class I protein complex GO:0042612 9.13 HLA-A HLA-B HLA-C

Biological processes related to Spondyloarthropathy according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.97 IL10 IL17A IL6 NLRP2 TNF
2 regulation of immune response GO:0050776 9.94 HLA-A HLA-B HLA-C IL4
3 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.83 HLA-A HLA-B HLA-C
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 IFNG IL2 IL6
5 type I interferon signaling pathway GO:0060337 9.8 HLA-A HLA-B HLA-C
6 response to glucocorticoid GO:0051384 9.79 IL10 IL6 TNF
7 positive regulation of T cell proliferation GO:0042102 9.79 IL2 IL4 IL6
8 humoral immune response GO:0006959 9.77 IFNG IL6 TNF
9 positive regulation of DNA binding transcription factor activity GO:0051091 9.76 IL10 IL6 TNF TNFSF11
10 regulation of signaling receptor activity GO:0010469 9.76 IFNG IL10 IL17A IL2 IL4 IL6
11 negative regulation of inflammatory response GO:0050728 9.73 IL10 IL2 NLRP2 PTGIS
12 antigen processing and presentation GO:0019882 9.71 HLA-A HLA-B HLA-C
13 negative regulation of nitric oxide biosynthetic process GO:0045019 9.68 IL10 PTGIS
14 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.68 IFNG TNF
15 regulation of regulatory T cell differentiation GO:0045589 9.67 IFNG IL2
16 regulation of osteoclast differentiation GO:0045670 9.67 TNF TNFSF11
17 negative regulation of growth of symbiont in host GO:0044130 9.67 IL10 TNF
18 interferon-gamma-mediated signaling pathway GO:0060333 9.67 HLA-A HLA-B HLA-C IFNG
19 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.66 IL10 TNF
20 positive regulation of immunoglobulin secretion GO:0051024 9.65 IL2 IL6
21 negative regulation of lipid storage GO:0010888 9.65 IL6 TNF
22 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.65 HLA-A HLA-B HLA-C
23 positive regulation of isotype switching to IgG isotypes GO:0048304 9.64 IL2 IL4
24 endothelial cell apoptotic process GO:0072577 9.63 IL10 TNF
25 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL10 IL4
26 negative regulation of cytokine secretion involved in immune response GO:0002740 9.59 IL10 TNF
27 type 2 immune response GO:0042092 9.58 IL10 IL4
28 protection from natural killer cell mediated cytotoxicity GO:0042270 9.56 HLA-A HLA-B
29 positive regulation of osteoclast differentiation GO:0045672 9.56 IFNG IL17A TNF TNFSF11
30 cytokine-mediated signaling pathway GO:0019221 9.56 IL10 IL17A IL2 IL4 IL6 MMP3
31 positive regulation of interleukin-23 production GO:0032747 9.55 IFNG IL17A
32 regulation of isotype switching GO:0045191 9.52 IL10 IL4
33 receptor biosynthetic process GO:0032800 9.51 IL10 TNF
34 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.5 HLA-A HLA-B HLA-C
35 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
36 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 IFNG TNF
37 immune response GO:0006955 9.36 HLA-A HLA-B HLA-C IFNG IL10 IL17A
38 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 IL10 IL17A IL2 IL4 IL6 TNF
39 immune system process GO:0002376 10.06 HLA-A HLA-B HLA-C IL2 NLRP2

Molecular functions related to Spondyloarthropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL10 IL2 IL4 IL6
2 cytokine activity GO:0005125 9.23 IFNG IL10 IL17A IL2 IL4 IL6
3 peptide antigen binding GO:0042605 9.13 HLA-A HLA-B HLA-C
4 protein binding GO:0005515 10.16 ALDOA HLA-A HLA-B HLA-C IFNG IL10

Sources for Spondyloarthropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....